PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models

Genes and Cancer

Volumn 4, Issue 11-12, 2013, Pages 524-534

  Kawar, Nada ^a   Maclaughlan, Shannon ^b   Horan, Timothy C ^a   Uzun, Alper ^c   Lange, Thilo S ^a   Kim, Kyu K ^a   Hopson, Russell ^a   Singh, Ajay P ^d   Sidhu, Preetpal S ^e   Glass, Kyle A ^c   Shaw, Sunil ^c   Padbury, James F ^c   Vorsa, Nicholi ^d   Arnold, Leggy A ^e   Moore, Richard G ^a   Brard, Laurent ^f   Singh, Rakesh K ^a  

^a BROWN UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^f SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antitumor efficacy; endometrial cancer; hypercalcemia; ovarian cancer; vitamin D

Indexed keywords

ACTIN; CALCITRIOL; ERGOCALCIFEROL DERIVATIVE; PT19C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CONTROLLED STUDY; DRUG SYNTHESIS; ENDOMETRIUM CANCER; FEMALE; FOCAL ADHESION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERCALCEMIA; MICROSCOPY; MOLECULAR DOCKING; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; TOXICITY TESTING; TRANSACTIVATION ASSAY; TUMOR XENOGRAFT;

EID: 84891507095     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913507575     Document Type: Article

References (20)

1. Bouillon R,Okamura WH,Norman AW.Structure-function relationships in the vitamin D endocrine system.Endocr Rev. 1995;16:200-57.
2. Deeb KK,Trump DL,Johnson CS.Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.Nat Rev Cancer. 2007;7:684-700.
3. Lambert JR,Young CD,Persons KS,Ray R.Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells.Biochem Biophys Res Commun. 2007;361:189-95.
4. Osborn JL,Schwartz GG,Bahnson R,Smith DC,Trump DL.Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.Urol Oncol. 1995;1:195-8.
5. Prudencio JN,Akutsu N,Benlimame T, et al.Action of low calcemic 1α,25 dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.J Natl Cancer Inst. 2001;93:745-53.
6. Kawa S,Yoshizawa K,Nikaido T,Kiyosawa K.Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines.J Steroid Biochem Mol Biol. 2005;97:173-7.
7. Brard L,Lange TS,Robison K, et al.Evaluation of the first ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.Gynecol Oncol. 2011;123:370-8.
8. Brard L,Kalkunte S,Singh RK.Heterocyclic and derivatives thereof and methods of manufacture and therapeutic use. 2007;:.
9. Moore RG,Lange TS,Robinson K, et al.Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.PLoS One. 2012;7 (4):.
10. Stuckey A,Fischer A,Miller DH, et al.Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.BMC Cancer. 2011;11:308.
11. Bury Y,Stienmeyer A,Carlberg C.Structure-activity relationship of carboxylic ester antagonists of the vitamin D3 receptor.Mol Pharmacol. 2000;58:1067-74.
12. Morris GM,Goodsell DS,Halliday RS, et al.Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function.J Comput Chem. 1998;19:1639-62.
13. Korch C,Spillman MA,Jackson TA, et al.DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.Gynecol Oncol. 2012;127:241-8.
14. Maruyama W,Irie S,Sato TA.Morphological changes in the nucleus and actin cytoskeleton in the process of Fas-induced apoptosis in Jurkat T cells.Histochem J. 2000;32:495-503.
15. Walling EA,Krafft GA,Ware BR.Actin assembly activity of cytochalasins and cytochalasin analogs assayed using fluorescence photobleaching recovery.Arch Biochem Biophys. 1988;264:321-32.
16. Rao JY,Jin YS,Zheng Q,Cheng J,Tai J,Hemstreet GP.Alterations of the actin polymerization status as an apoptotic morphological effector in HL-60 cells.J Cell Biochem. 1999;75:686-97.
17. Yamazaki Y,Tsuruga M,Zhou D,Fujita Y,Shang X.Cytoskeletal disruption accelerates caspase-3 activation and alters the intracellular membrane reorganization in DNA damage-induced apoptosis.Exp Cell Res. 2000;259:64-78.
18. Suria H,Chau LA,Negrou E,Kelvin DJ,Madrenas J.Cytoskeletal disruption induces T cell apoptosis by a caspase-3 mediated mechanism.Life Sci. 1999;65:2697-707.
19. Teichert A,Arnold LA,Otieno S, et al.Quantification of the vitamin D receptor-coregulator interaction.Biochemistry. 2009;48:1454-61.
20. Berman HM,Westbrook J,Feng Z, et al.The protein data bank.Nucleic Acids Res. 2000;28:235-42.